The registry looks to collect and analyze data from over 6,000 patients with major depressive disorder who have been treated with NeuroStar Advanced Therapy to better understand outcomes and usefulness of the therapy in a clinical setting.
“In the long term, the research obtained from this registry has the potential to change the way we provide care to people with chronic depression. The information collected over the years will equip physicians with case histories and the necessary research to tailor the most effective treatment plans. This, in turn, will allow us to better understand and ultimately meet the needs of these patients,” Dr. Kenneth Pages of Tampa, Fla.’s TMS of South Tampa said in prepared remarks.
Malvern, Penn.-based NeuroStar said it has published 23 studies supporting the efficacy, safety and durability of NeuroStar transcranial magnetic stimulation.
Data from open-label clinical trials indicated that 58% of people treated with the therapy responded significantly, with 37% achieving complete remission of depressive symptoms. A total of 68% retained their treatment response after 12 months, the company said.
“There are currently more than 740 NeuroStar providers across the U.S., with over one million treatments delivered to-date. We are thrilled to roll out this registry to participating physicians and are striving for it to become the largest depression patient database ever. The primary objective of the multi-site, observational dataset is to report disease state outcomes for MDD patients treated with NeuroStar Advanced Therapy using validated clinical rating scales, thus enabling better patient care through easy, efficient outcomes analysis,” chief medical officer Dr. Mark Demitrack said in a press release.
The post NeuroStar launches real-world registry for TMS therapy in depression appeared first on MassDevice.
from MassDevice http://ift.tt/2eZ960s
Cap comentari:
Publica un comentari a l'entrada